Research Funded by ASF

The mission of the Alport Syndrome Foundation (ASF) is to find better treatment protocols and a cure for Alport Syndrome by accumulating and directing resources to support research. The following research projects were funded by ASF through the Annual Campaign for Healthy Kidneys, individual fundraising, and collaboration with the Kidney Foundation of Canada (KFOC)/Macquarie Foundation.

Nephroprotective and antifibrotic potential of microRNA-21 in the COL4A3 knockout mouse model of Alport syndrome
Dr. Oliver Gross, University Medical Centre Göttingen (Germany)
Awarded 2013

Dr. Oliver Gross was awarded $98,500 for a one year study on the Nephroprotective and antifibrotic potential of microRNA-21 in the COL4A3 knockout mouse model of Alport syndrome. The research project goals are to evaluate anti microRNA-21 therapy in reducing renal fibrosis and promoting podocyte functioning. This award was funded by ASF and KFOC/Macquarie Foundation.

Click here to read Dr. Gross’s full research abstract

Derivation and Characterisation of induced pluripotent stem cell lines from patients with X-Linked Alport syndrome – a model for examining mechanisms and therapies
Dr. Judy Savige, University of Melbourne (Australia)
Dr. Sharon Ricardo, Monash University (Australia)
Awarded 2013

Dr. Judy Savige and Dr. Sharon Ricardo were awarded $98,600 for a one year study on the Derivation and Characterisation of induced pluripotent stem cell lines from patients with X-Linked Alport syndrome – a model for examining mechanisms and therapies. The research project will use reprogrammed adult stem cells to generate podocytes which will be examined to evaluate how Alport syndrome mutations are produced and to investigate treatments targeting these mutations. This award was funded by ASF and KFOC/Macquarie Foundation.

Click here to read Dr. Savige’s and Dr. Ricardo’s full research abstract

Defining Efficacy of Combination Drug Therapy in Alport Mice
Dr. Jeffrey Miner, Washington University (Missouri, USA)
Awarded 2012

Dr, Miner was awarded $100,000 for a one year study on Defining Efficacy of Combination Drug Therapy in Alport Mice. The goal of this proposal is to determine whether combined therapy with both and ACE inhibitor and a proprietary inhibitor of chemokine receptor 2 and 5 (CCR2 and CCR5) activation will have a synergistic effect at slowing Alport disease progression and will extend life span even more than the ACE inhibitor alone.

Click here to read Dr. Miner’s full research abstract

Click here to read about Dr. Miner’s recent research on gene therapy

Amniotic Fluid Stem Cells (AFSC) and Alport Syndrome
Dr. Laura Perin, Saban Research Institute at Children’s Hospital Los Angeles (California, USA)
Awarded 2011

Dr. Perin was awarded $100,000 for a two-year research project on Amniotic Fluid Stem Cells (AFSC) and Alport Syndrome. Dr. Perin proposes to use Amniotic Fluid Stem Cells (AFSC) as a novel approach to reversing fibrosis in AS.

Click here for more information on Amniotic Fluid Stem Cells (AFSC)
Click here for to read Dr. Perin’s full research abstract

Alport Syndrome Treatments and Outcomes Registry (ASTOR)
Dr. Clifford Kashtan, University of Minnesota (USA)

The Alport Syndrome Treatments and Outcomes Registry (ASTOR) was established in 2007 with the goal of creating a secure, comprehensive electronic database of North American families with Alport syndrome, in order to stimulate and facilitate clinical research in Alport syndrome, including trials of promising therapies. The Alport Syndrome Foundation has provided much needed funding to keep ASTOR a fully functioning research entity.

Click here to read updates on the ASTOR team’s current projects